NY-BENTALLGREENOAK
20.10.2021 14:02:05 CEST | Business Wire | Press release
BentallGreenOak (BGO) announced today that, in a consecutive run of industry leadership now marking 11 years, its global real estate investment platform has achieved a new high mark for exceptional performance in the annual Global Real Estate Sustainability Benchmark (GRESB). Four of BGO’s flagship investment strategies, already amongst the best performing funds in their global categories, achieved five star ratings and higher scores in 2021, reinforcing a firm-wide commitment to enhanced, year-over-year performance in ESG across its platform. For the first time in BGO’s 11 years of GRESB participation, all BGO funds participating in the Development module — which measures an entity’s efforts to address ESG issues during a building’s design, construction and renovation phases — ranked first in their peer group, achieving Sector Leader status.
Highlights from BentallGreenOak’s 2021 GRESB scores:
- All BGO Funds scored 100% on the Management component of GRESB, demonstrating leadership in firm-level ESG policies and programs.
- BGO Diversified, Prime Canadian Property Fund and the Sun Life General Account scored 100% on all Social & Governance indicators.
- BGO Diversified US Property Fund achieved a 5-star rating with a score of 90/100, and ranked first and named Sector Leader in Developments.
- WELPUT achieved a 5-star rating with a score of 90/100.
- Prime Canadian Property Fund achieved a 5-star rating with a score of 89/100, and ranked first and named Sector Leader in Developments.
- The Sun Life General Account achieved a 5-star rating with a score of 89/100, and ranked first and named Sector Leader in Developments.
“The pursuit of excellence in ESG is a firm-wide, collective effort and defining characteristic of the culture at BentallGreenOak, and every year the bar is set higher for us to showcase what is truly possible for impact and sustainable investing in the commercial real estate industry,” said Anna Murray, Managing Director and Global Head of ESG, BentallGreenOak. “A cross-functional array of teams at BGO dig deep into each and every asset to realize new benchmarks for efficiency, sustainability performance, climate resiliency and a reduced environmental footprint that demonstrate how excellence in ESG is part of the enduring and differentiated value that we offer our investor clients, tenants and broader stakeholders.”
"BentallGreenOak's decade of sustained ESG success includes repeat GRESB Sector Leader awards and multiple GRESB 5-Star rankings," said Dan Winters, GRESB Head of Americas. "Each successive year BentallGreenOak raises the bar, driving the institutional real estate industry in a competitive race to the top."
“The increased focus on ESG from the commercial real estate investment industry is ushering in a new era where intensifying investor expectations, evolving public sentiment and tangible improvements from asset managers are unstoppable forces that must confront the challenge of climate change that we are experiencing today and will continue to experience in the decades ahead,” said Sonny Kalsi, Co-CEO, BentallGreenOak. “We celebrate our progress at BGO and our 11th consecutive year of out-performance in the Global Real Estate Sustainability Benchmark (GRESB), and we know that the work is not done. We have set our unwavering intention as a firm to continue to lead the industry and strive for new high marks for sustainability in the built environment.”
In 2021, more than 1,520 property companies, real estate investment trusts (REITs), funds and developers participated in GRESB’s Real Estate Assessment, representing USD 5.7 trillion AUM. The Assessment covers nearly 117,000 assets across 64 countries.
About BentallGreenOak
BentallGreenOak is a leading, global real estate investment management advisor and a globally-recognized provider of real estate services. BentallGreenOak serves the interests of more than 750 institutional clients with approximately $69 billion USD of assets under management (as of June 30, 2021) and expertise in the asset management of office, industrial, multi-residential, retail and hospitality property across the globe. BentallGreenOak has offices in 24 cities across twelve countries with deep, local knowledge, experience, and extensive networks in the regions where we invest in and manage real estate assets on behalf of our clients in primary, secondary and co-investment markets.
BentallGreenOak is a part of SLC Management, which is the alternatives asset management business of Sun Life.
The assets under management shown above includes real estate equity and mortgage investments managed by the BentallGreenOak group of companies and their affiliates, and as of 1Q21, includes certain uncalled capital commitments for discretionary capital until they are legally expired and excludes certain uncalled capital commitments where the investor has complete discretion over investment.
For more information, please visit www.bentallgreenoak.com .
About GRESB
GRESB is a mission-driven and industry-led organization providing standardized and validated Environmental, Social and Governance (ESG) data to financial markets. Established in 2009, GRESB has become the leading ESG benchmark for real estate and infrastructure investments across the world, used by 140 institutional and financial investors to inform decision-making.
For more information, visit www.GRESB.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211020005084/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom